Hepatitis B Therapy

Lamivudine causes drug-resistant mutants in children with chronic hepatitis B

Published in Hepatitis Weekly, April 7th, 2003

by Sonia Nichols, senior medical writer - Children infected with hepatitis B virus (HBV) who don't respond to interferon therapy are likely to develop drug-resistant mutants when they subsequently take lamivudine.

That is what happened to children enrolled in a prospective open trial to treat chronic hepatitis B infections with lamivudine, according to Corina Hartman and colleagues at Meyer Children's Hospital of Haifa in Haifa, Israel.

Each of the 20 children, aged 8.5 to 19 years, had previously received interferon, a standard therapy for chronic hepatitis B, and none had responded to that treatment.

"At the end of 1 year, HBV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-04-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry